CA9 and breast carcinoma: Furthermore, delivery of novel ureido sulfonamide [102] and glycosyl coumarin [103] inhibitors of CAIX into human and mouse models of orthotopic, CAIX-positive breast cancer resulted in significant inhibition of primary tumor growth.